Given the pivotal role in enhancing tumourigenesis resistance with the TME, targeting IL-8 signalling remains a promising therapeutic approach to disrupt the tumour-, TME-, and IME-driven mechanisms of disease progression and treatment resistance. Here, CXCL8 is linked to neoplasm.